Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: A meta-analysis on 9 randomized controlled trials

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1265-1275

  Yu, Yong ^a   Xu, Xun ^a   Du, Ziyan ^a   Shi, Minhua ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Carboplatin; Carcinoma; Cisplatin; Docetaxel; Gemcitabine; Non small cell lung; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ADVANCED CANCER; ANALYTICAL PARAMETERS; ANEMIA; ARTICLE; BLOOD TOXICITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TIME TO PROGRESSION; TREATMENT RESPONSE; COMPARATIVE STUDY; LUNG TUMOR; PATHOLOGY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; PLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84862302379     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1833-y     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Novello S, Le Chevalier T (2003) Chemotherapy for non-smallcell lung cancer, Part 1: early-stage disease. Oncology (Williston Park) 17:357-364
3. Azzoli CG, Baker SJ, Temin S et al (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266
4. NCCN Non-Small Cell Lung Cancer Panel Members (2011) Non-small cell lung cancer. NCCN clinical practice guidelines in oncology version 3, 2011. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
5. Pujol JL, Breton JL, Gervais R et al (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic nonsmall- cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602-610 (Pubitemid 40613327)
6. Georgoulias V, Ardavanis A, Tsiafaki X et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced nonsmall- cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937-2945 (Pubitemid 46224112)
7. Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum- based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478-1484 (Pubitemid 32488857)
8. Julian PT Higgins, Douglas G Altman, Jonathan AC Sterne (2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (ed) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org
9. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834 (Pubitemid 28562978)
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560 (Pubitemid 37088507)
11. Rubio JC, Estevez SV, Rivera FV et al (2006) Gemcitabine/ Docetaxel (GD) vs Gemcitabine/Cisplatin (GC) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006 ASCO annual meeting proceedings part I, vol 24, no. 18S (June 20 Supplement): 17017
12. Rubio JC, Estevez SV, Rivera FV et al (2006) A randomized phase IIB trial of gemcitabine and cisplatin (GC) versus gemcitabine and docetaxel (GD) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). an galician lung cancer group study. ESMO annual meeting Abstract 2006. 751P
13. Solomon B, Bunn PA Jr (2005) Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: Similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treat Rev 31:571-576 (Pubitemid 41614814)
14. Takiguchi Y, Katakami N, Yoshimori K et al (2004) Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small cell lung carcinoma (NSCLC): a randomized phase II study by the Japan lung cancer cooperative clinical study group. EMSO annual meeting Abstract 2004. 635PD
15. Georgoulias V, Ardavanis A, Tsiafaki X et al (2004) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced nonsmall cell lung cancer: a phase III randomized trial. ESMO annual meeting Abstract 2004, 637PD
16. Binder D, Beinert T, Schweisfurth H et al (2004) Docetaxelgemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial. ESMO Ann Meet Abstr 2004:7071
17. Binder D, Sailer V, Schweigert M et al (2002) A randomized phase II study of gemcitabine/docetaxel vs gemcitabine/cisplatin followed by docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Society of Clinical Oncology 2002
18. Kakolyris S, Tsiafaki X, Agelidou A et al (2002) Preliminary results of a multicentre randomised phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer [abstract]. In: Proceedings of the American Society of Clinical Oncology 2002
19. Georgoulias V, Samonis G, Papadakis E et al (2001) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34(Suppl 4):S47-S51
20. Georgoulias V, Papadakis E, Alexopoulos A et al (1999) Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial. ASCO annual meeting Abstract 1999, Abstract No:1778
21. Novello S, Falcone A, Crino L et al (2009) Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer 66:327-332
22. Rubio JC, Vazquez S, Vazquez F et al (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 64:379-384
23. Rigas JR, Carey M, Dragnev KH et al (2008) Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112. J Clin Oncol 26: May 20 suppl, abstr 8100
24. Binder D, Schweisfurth H, Grah C et al (2007) Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Cancer Chemother Pharmacol 60:143-150 (Pubitemid 46643725)
25. Katakami N, Takiguchi Y, Yoshimori K et al (2006) Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan lung cancer cooperative clinical study group. J Thorac Oncol 1:447-453 (Pubitemid 47181422)
26. Gamaz M, Taright TMS (2006) Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2006 ASCO annual meeting proceedings part I, vol 24, no 18S (June 20 Supplement): 17116
27. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
28. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a metaanalysis. J Thorac Oncol 2:845-853 (Pubitemid 47361027)
29. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):116-119
30. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, ShepherdFA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926-2936 (Pubitemid 46224111)
31. Chen S, Zhang J, Wang R, Luo X, Chen H (2010) The platinumbased treatments for advanced non-small cell lung cancer, is low/ negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70:63-70